Tech Company Financing Transactions

Prevail Therapeutics Funding Round

On 3/9/2018, Prevail Therapeutics landed $75 million in Series A investment from Adage Capital Management, Alexandria Venture Investments and Boxer Capital.

Transaction Overview

Announced On
3/9/2018
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series A
Investors

Adage Capital Management

Alexandria Venture Investments

Boxer Capital

BVF Partners

EcoR1 Capital Management

Omega Funds

OrbiMed (Jonathan Silverstein)

Pontifax Fund

RA Capital

Proceeds Purpose
The proceeds of the Series A financing will be used to advance Prevail's pipeline of AAV-based (adeno-associated virus) therapeutics targeting lysosomal dysfunction to treat patients with genetically-defined neurodegenerative diseases.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
430 East 29th St. 1520
New York, NY 10016
USA
Email Address
Overview
Prevail Therapeutics is a biotech company based in New York City that is developing therapeutics for brain disorders such as Parkinson's disease. Prevail is establishing a pipeline of programs that includes discovery-phase and preclinical development efforts.
Profile
Prevail Therapeutics LinkedIn Company Profile
Social Media
Prevail Therapeutics Company Twitter Account
Company News
Prevail Therapeutics News
Facebook
Prevail Therapeutics on Facebook
YouTube
Prevail Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Asa Abeliovich
  Asa Abeliovich LinkedIn Profile  Asa Abeliovich Twitter Account  Asa Abeliovich News  Asa Abeliovich on Facebook
Chief Financial Officer
Brett Kaplan
  Brett Kaplan LinkedIn Profile  Brett Kaplan Twitter Account  Brett Kaplan News  Brett Kaplan on Facebook
Chief Medical Officer
Jeffrey Sevigny
  Jeffrey Sevigny LinkedIn Profile  Jeffrey Sevigny Twitter Account  Jeffrey Sevigny News  Jeffrey Sevigny on Facebook
Chief Technical Officer
Yong Dai
  Yong Dai LinkedIn Profile  Yong Dai Twitter Account  Yong Dai News  Yong Dai on Facebook
VP - Bus. Development
Franz Hefti
  Franz Hefti LinkedIn Profile  Franz Hefti Twitter Account  Franz Hefti News  Franz Hefti on Facebook
VP - Bus. Development
Emily Minkow
  Emily Minkow LinkedIn Profile  Emily Minkow Twitter Account  Emily Minkow News  Emily Minkow on Facebook
VP - General Counsel
Kira Schwartz
  Kira Schwartz LinkedIn Profile  Kira Schwartz Twitter Account  Kira Schwartz News  Kira Schwartz on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/9/2018: Mojio venture capital transaction
Next: 3/9/2018: Zebi venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary